-
-
[1] Alegre ML, Florquin S, Goldman M. Cellular mechanisms underlying acute graft rejection: time for reassessment[J]. Curr Opin Immunol,2007,19(5):563-568. doi: 10.1016/j.coi.2007.07.019 [2] Li XC. The significance of non-T-cell pathways in graft rejection: implications for transplant tolerance[J]. Transplantation,2010,90(10):1043-1047. doi: 10.1097/TP.0b013e3181efcfe9 [3] Kroemer A, Edtinger K, Li XC. The innate natural killer cells in transplant rejection and tolerance induction[J]. Curr Opin Organ Transplant,2008,13(4):339-343. doi: 10.1097/MOT.0b013e3283061115 [4] Sun JC, Beilke JN, Lanier LL. Adaptive immune features of natural killer cells[J]. Nature,2009,457(7229):557-561. doi: 10.1038/nature07665 [5] Vivier E, Tomasello E, Baratin M, et al. Functions of natural killer cells[J]. Nat Immunol,2008,9(5):503-510. doi: 10.1038/ni1582 [6] van der Touw W, Bromberg JS. Natural killer cells and the immune response in solid organ transplantation[J]. Am J Transplant,2010,10(6):1354-1358. doi: 10.1111/ajt.2010.10.issue-6 [7] Benichou G, Yamada Y, Aoyama A, et al. Natural killer cells in rejection and tolerance of solid organ allografts[J]. Curr Opin Organ Transplant,2011,16(1):47-53. doi: 10.1097/MOT.0b013e32834254cf [8] Lin Y, Vandeputte M, Waer M. Natural killer cell-and macrophage-mediated rejection of concordant xenografts in the absence of T and B cell responses[J]. J Immunol,1997,158(12):5658-5667. http://cn.bing.com/academic/profile?id=1536891815&encoded=0&v=paper_preview&mkt=zh-cn [9] Maier S, Tertilt C, Chambron N, et al. Inhibition of natural killer cells results in acceptance of cardiac allografts in CD28-/- mice[J]. Nat Med,2001,7(5):557-562. doi: 10.1038/87880 [10] Kroemer A, Xiao X, Degauque N, et al. The innate NK cells, allograft rejection, and a key role for IL-15[J]. J Immunol,2008,180(12):7818-7826. doi: 10.4049/jimmunol.180.12.7818 [11] Cooper MA, Elliott JM, Keyel PA, et al. Cytokine-induced memory-like natural killer cells[J]. Proc Natl Acad Sci U S A,2009,106(6):1915-1919. doi: 10.1073/pnas.0813192106 [12] Jungraithmayr W, Codarri L, Bouchaud G, et al. Cytokine complex-expanded natural killer cells improve allogeneic lung transplant function via depletion of donor dendritic cells[J]. Am J Respir Crit Care Med,2013,187(12):1349-1359. doi: 10.1164/rccm.201209-1749OC [13] Yu G, Xu X, Vu MD, et al. NK cells promote transplant tolerance by killing donor antigen-presenting cells[J]. J Exp Med,2006,203(8):1851-1858. doi: 10.1084/jem.20060603 [14] Laffont S, Seillet C, Ortaldo J, et al. Natural killer cells recruited into lymph nodes inhibit alloreactive T-cell activation through perforin-mediated killing of donor allogeneic dendritic cells[J]. Blood,2008,112(3):661-671. doi: 10.1182/blood-2007-10-120089 [15] Garrod KR, Liu FC, Forrest LE, et al. NK cell patrolling and elimination of donor-derived dendritic cells favor indirect alloreactivity[J]. J Immunol, 2010,184(5):2329-2236. doi: 10.4049/jimmunol.0902748 [16] van der Touw W, Burrell B, Lal G, et al. NK cells are required for costimulatory blockade induced tolerance to vascularized allografts[J]. Transplantation,2012,94(6):575-584. doi: 10.1097/TP.0b013e318264d3c4 [17] Pratschke J, Stauch D, Kotsch K. Role of NK and NKT cells in solid organ transplantation[J]. Transpl Int,2009,22(9):859-868. doi: 10.1111/tri.2009.22.issue-9 [18] Roy S, Barnes PF, Garg A, et al. NK cells lyse T regulatory cells that expand in response to an intracellular pathogen[J]. J Immunol,2008,180(3):1729-1736. doi: 10.4049/jimmunol.180.3.1729 [19] Lawrence T, Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity[J]. Nat Rev Immunol,2011,11(11):750-761. doi: 10.1038/nri3088 [20] Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease[J]. Nature,2013,496(7446):445-455. doi: 10.1038/nature12034 [21] Tugal D, Liao X, Jain MK. Transcriptional control of macrophage polarization[J]. Arterioscler Thromb Vasc Biol,2013,33(6):1135-1144. doi: 10.1161/ATVBAHA.113.301453 [22] Guo C, Buranych A, Sarkar D, et al. The role of tumor-associated macrophages in tumor vascularization[J]. Vasc Cell,2013,5(1):20. doi: 10.1186/2045-824X-5-20 [23] Chinetti-Gbaguidi G, Staels B. Macrophage polarization in metabolic disorders: functions and regulation[J]. Curr Opin Lipidol,2011,22(5):365-372. doi: 10.1097/MOL.0b013e32834a77b4 [24] Benoit M, Desnues B, Mege JL. Macrophage polarization in bacterial infections[J]. J Immunol,2008,181(6):3733-3739. doi: 10.4049/jimmunol.181.6.3733 [25] Murai M, Hasegawa Volk M, Lee HM. Macrophage cytophilic antibodies in beagle renal allograft[J]. Surg Forum,1975,26:346-348. http://cn.bing.com/academic/profile?id=2463434941&encoded=0&v=paper_preview&mkt=zh-cn [26] Cruse JM, Whitten HD, Lewis GK, et al. Facilitation of macrophage-mediated destruction of allogeneic fibrosarcoma cells by tumor-enhancing IgG 2 in vitro[J]. Transplant Proc,1973,5(1):961-967. http://cn.bing.com/academic/profile?id=1557287323&encoded=0&v=paper_preview&mkt=zh-cn [27] Debray-Sachs M, Dy M, Hamburger J. Role of macrophage activation in allograft immunity: in vivo studies[J]. Ann Immunol,1979,130C(5):721-733. http://cn.bing.com/academic/profile?id=1497538682&encoded=0&v=paper_preview&mkt=zh-cn [28] Sund S, Reisaeter AV, Scott H, et al. Glomerular monocyte/macrophage influx correlates strongly with complement activation in 1-week protocol kidney allograft biopsies[J]. Clin Nephrol,2004,62(2):121-130. http://cn.bing.com/academic/profile?id=2318950580&encoded=0&v=paper_preview&mkt=zh-cn [29] Rowshani AT, Vereyken EJ. The role of macrophage lineage cells in kidney graft rejection and survival[J]. Transplantation,2012,94(4):309-318. doi: 10.1097/TP.0b013e318250c10f [30] Mannon RB. Macrophages: contributors to allograft dysfunction, repair, or innocent bystanders?[J].Curr Opin Organ Transplant,2012,17(1):20-25. doi: 10.1097/MOT.0b013e32834ee5b6 [31] Azzawi M, Hasleton PS, Hutchinson IV. TNF-alpha in acute cardiac transplant rejection[J]. Cytokines Cell Mol Ther,1999,5(1):41-49. http://cn.bing.com/academic/profile?id=2403586231&encoded=0&v=paper_preview&mkt=zh-cn [32] Wyburn K, Wu H, Yin J, et al. Macrophage-derived interleukin-18 in experimental renal allograft rejection[J]. Nephrol Dial Transplant,2005,20(4):699-706. doi: 10.1093/ndt/gfh712 [33] Fahim T, B hmig GA, Exner M, et al. The cellular lesion of humoral rejection: predominant recruitment of monocytes to peritubular and glomerular capillaries[J]. Am J Transplant,2007,7(2):385-393. doi: 10.1111/ajt.2007.7.issue-2 [34] Riquelme P, Tomiuk S, Kammler A, et al. IFN-γ-induced iNOS expression in mouse regulatory macrophages prolongs allograft survival in fully immunocompetent recipients[J]. Mol Ther,2013,21(2):409-422. doi: 10.1038/mt.2012.168 [35] Getts DR, Turley DM, Smith CE, et al. Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cells[J]. J Immunol,2011,187(5):2405-2417. doi: 10.4049/jimmunol.1004175 [36] Broichhausen C, Riquelme P, Geissler EK, et al. Regulatory macrophages as therapeutic targets and therapeutic agents in solid organ transplantation[J]. Curr Opin Organ Transplant,2012,17(4):332-342. http://cn.bing.com/academic/profile?id=2076216139&encoded=0&v=paper_preview&mkt=zh-cn [37] Magil AB. Monocytes/macrophages in renal allograft rejection[J]. Transplant Rev, 2009,23(4):199-208. doi: 10.1016/j.trre.2009.06.005 [38] Kitchens WH, Chase CM, Uehara S, et al. Macrophage depletion suppresses cardiac allograft vasculopathy in mice[J]. Am J Transplant,2007,7(12):2675-2682. doi: 10.1111/ajt.2007.7.issue-12 [39] Leibovich SJ, Polverini PJ, Fong TW, et al. Production of angiogenic activity by human monocytes requires an L-arginine/nitric oxide-synthase-dependent effector mechanism[J]. Proc Natl Acad Sci U S A,1994,91(10):4190-4194. doi: 10.1073/pnas.91.10.4190 [40] Grandaliano G, Gesualdo L, Ranieri E, et al. Monocyte chemotactic peptide-1 expression and monocyte infiltration in acute renal transplant rejection[J]. Transplantation,1997,63(3):414-420. doi: 10.1097/00007890-199702150-00015 [41] Leibovich SJ, Polverini PJ, Shepard HM, et al. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha[J]. Nature,1987,329(6140):630-632. doi: 10.1038/329630a0 [42] Reinders ME, Rabelink TJ, Briscoe DM. Angiogenesis and endothelial cell repair in renal disease and allograft rejection[J]. J Am Soc Nephrol,2006,17(4):932-942. doi: 10.1681/ASN.2005121250 [43] Li X, Chen Y, Tian L, et al. Increased iNOS-expressing macrophage in long-term surviving rat small-bowel grafts[J]. Am J Surg,2007,194(2):248-254. doi: 10.1016/j.amjsurg.2006.09.032 [44] Dehmel S, Wang S, Schmidt C, et al. Chemokine receptor Ccr5 deficiency induces alternative macrophage activation and improves long-term renal allograft outcome[J]. Eur J Immunol,2010,40(1):267-278. http://cn.bing.com/academic/profile?id=1981754960&encoded=0&v=paper_preview&mkt=zh-cn [45] Wang C, Tay SS, Tran GT, et al. Donor IL-4-treatment induces alternatively activated liver macrophages and IDO-expressing NK cells and promotes rat liver allograft acceptance[J]. Transpl Immunol,2010,22(3/4):172-178. [46] Niess JH, Brand S, Gu X, et al. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance[J]. Science,2005,307(5707):254-258. doi: 10.1126/science.1102901 [47] Steinman RM, Banchereau J. Taking dendritic cells into medicine[J]. Nature,2007,449(7161):419-426. doi: 10.1038/nature06175 [48] Brenk M, Scheler M, Koch S, et al. Tryptophan deprivation induces inhibitory receptors ILT3 and ILT4 on dendritic cells favoring the induction of human CD4+ CD25+ Foxp3+ T regulatory cells[J]. J Immunol,2009,183(1):145-154. doi: 10.4049/jimmunol.0803277 [49] Lucas M, Schachterle W, Oberle K, et al. Dendritic cells prime natural killer cells by trans-presenting interleukin 15[J]. Immunity,2007,26(4):503-517. doi: 10.1016/j.immuni.2007.03.006 [50] Shortman K, Liu YJ. Mouse and human dendritic cell subtypes[J]. Nat Rev Immunol,2002,2(3):151-161. doi: 10.1038/nri746 [51] Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance[J]. Nat Rev Immunol,2007,7(8):610-621. doi: 10.1038/nri2132 [52] Thomson AW. Tolerogenic dendritic cells: all present and correct?[J]. Am J Transplant,2010,10(2):214-219. doi: 10.1111/ajt.2010.10.issue-2 [53] Tokita D, Mazariegos GV, Zahorchak AF, et al. High PD-L1/CD86 ratio on plasmacytoid dendritic cells correlates with elevated T-regulatory cells in liver transplant tolerance[J]. Transplantation,2008,85(3):369-377. doi: 10.1097/TP.0b013e3181612ded [54] Lin KL, Fulton LM, Berginski M, et al. Intravital imaging of donor allogeneic effector and regulatory T cells with host dendritic cells during GVHD[J]. Blood,2014,123(10):1604-1614. doi: 10.1182/blood-2013-09-526020 [55] Ochando JC, Homma C, Yang Y, et al. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts[J]. Nat Immunol,2006,7(6):652-662. doi: 10.1038/ni1333 [56] Rogers NM, Isenberg JS, Thomson AW. Plasmacytoid dendritic cells: no longer an enigma and now key to transplant tolerance?[J]. Am J Transplant,2013,13(5):1125-1133. doi: 10.1111/ajt.12229 [57] Zhong X, Gao W, Degauque N, et al. Reciprocal generation of Th1/Th17 and T(reg) cells by B1 and B2 B cells[J]. Eur J Immunol,2007,37(9):2400-2404. doi: 10.1002/(ISSN)1521-4141 [58] Mackay F, Schneider P, Rennert P, et al. BAFF AND APRIL: a tutorial on B cell survival[J]. Annu Rev Immunol,2003,21:231-264. doi: 10.1146/annurev.immunol.21.120601.141152 [59] Kirk AD, Turgeon NA, Iwakoshi NN. B cells and transplantation tolerance[J]. Nat Rev Nephrol,2010,6(10):584-593. doi: 10.1038/nrneph.2010.111 [60] Zarkhin V, Chalasani G, Sarwal MM. The yin and yang of B cells in graft rejection and tolerance[J]. Transplant Rev,2010,24(2):67-78. doi: 10.1016/j.trre.2010.01.004 [61] Terasaki PI, Cai J. Humoral theory of transplantation: further evidence[J]. Curr Opin Immunol,2005,17(5):541-545. doi: 10.1016/j.coi.2005.07.018 [62] Zarkhin V, Sarwal MM. The coin toss of B cells in rejection and tolerance: danger versus defense[J]. Semin Immunol,2012,24(2):86-91. doi: 10.1016/j.smim.2011.09.003 [63] Kwun J, Knechtle SJ. Overcoming chronic rejection:can it B?[J]. Transplantation,2009,88(8):955-961. doi: 10.1097/TP.0b013e3181b96646 [64] Halloran PF. Immunosuppressive drugs for kidney transplantation[J]. N Engl J Med,2004,351(26):2715-2729. doi: 10.1056/NEJMra033540 [65] Kocak B, Arpali E, Demiralp E, et al. Eculizumab for salvage treatment of refractory antibody-mediated rejection in kidney transplant patients: case reports[J]. Transplant Proc,2013,45(3):1022-1025. doi: 10.1016/j.transproceed.2013.02.062 [66] Locke JE, Magro CM, Singer AL, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection[J]. Am J Transplant,2009,9(1):231-235. http://cn.bing.com/academic/profile?id=1512745446&encoded=0&v=paper_preview&mkt=zh-cn [67] Perry DK, Burns JM, Pollinger HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production[J]. Am J Transplant,2009,9(1):201-209. http://cn.bing.com/academic/profile?id=1506252195&encoded=0&v=paper_preview&mkt=zh-cn [68] Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody-and cell-mediated acute rejection[J]. Transplantation,2008,86(12):1754-1761. doi: 10.1097/TP.0b013e318190af83 [69] Sberro-Soussan R, Zuber J, Suberbielle-Boissel C, et al. Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies[J]. Am J Transplant,2010,10(3):681-686. doi: 10.1111/ajt.2010.10.issue-3 [70] Burns AM, Ma L, Li Y, et al. Memory alloreactive B cells and alloantibodies prevent anti-CD154-mediated allograft acceptance[J]. J Immunol,2009,182(3):1314-1324. doi: 10.4049/jimmunol.182.3.1314 [71] Porcheray F, Wong W, Saidman SL, et al. B-cell immunity in the context of T-cell tolerance after combined kidney and bone marrow transplantation in humans[J]. Am J Transplant,2009,9(9):2126-2135. doi: 10.1111/ajt.2009.9.issue-9 [72] Deng S, Moore DJ, Huang X, et al. Cutting edge: transplant tolerance induced by anti-CD45RB requires B lymphocytes[J]. J Immunol,2007,178(10):6028-6032. doi: 10.4049/jimmunol.178.10.6028 [73] Le Texier L, Thebault P, Lavault A, et al. Long-term allograft tolerance is characterized by the accumulation of B cells exhibiting an inhibited profile[J]. Am J Transplant,2011,11(3):429-438. doi: 10.1111/j.1600-6143.2010.03336.x [74] Bouaziz JD, Yanaba K, Tedder TF. Regulatory B cells as inhibitors of immune responses and inflammation[J]. Immunol Rev,2008,224:201-214. doi: 10.1111/imr.2008.224.issue-1 [75] [CM(72.5mm]Iwata Y, Matsushita T, Horikawa M, et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells[J]. Blood,2011,117(2):530-541. [76] Blair PA, Noreña LY, Flores-Borja F, et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients[J]. Immunity,2010,32(1):129-140. doi: 10.1016/j.immuni.2009.11.009 [77] Redfield RR 3rd, Rodriguez E, Parsons R, et al. Essential role for B cells in transplantation tolerance[J]. Curr Opin Immunol,2011,23(5):685-691. doi: 10.1016/j.coi.2011.07.011
点击查看大图
计量
- 文章访问数: 98
- HTML全文浏览量: 26
- PDF下载量: 8
- 被引次数: 0